OptiNose is a pharmaceutical company that develops and commercializes products for ear, nose, throat, and allergy specialists in the US, including XHANCE for chronic rhinosinusitis, Onzetra Xsail for nasal migraines, and OPN-019 for antiseptic treatment. The company has licenses with Currax Pharmaceuticals and Inexia Limited for the commercialization and sale of products containing orexin receptor agonist and orexin receptor positive modulator molecules. Founded in 2000, OptiNose is headquartered in Yardley, Pennsylvania.